Business Wire

Analogix 10Gbps USB-C Re-Timers Ship in the Latest Generation Notebooks, Desktop PCs, Monitors, and Accessories

Jaa

Analogix Semiconductor, Inc. today announced the mass production of its ANX74xx family of USB-C™ re-timer solutions for notebooks, 2-in-1 convertible laptops, desktop PCs, monitors, and USB-C accessories, driven by demand from the PC and accessories market.

ANX7440, the first protocol aware re-timing mux bridging DisplayPort™ and USB 3.1 interfaces for Intel, AMD, and Nvidia CPUs/GPUs to the USB-C connector, is the first USB-C re-timer to pass interoperability at USB-IF and VESA plug-tests.

The Analogix re-timers implemented on the latest generation processor platforms offer the following advantages:

  • They are pure USB-C re-timers using Separate Reference Clock Independent of SSC (SRIS) and Bit-Level Re-timer (BLR) architectures, guaranteeing a loss compensation to recover up to 23dB channel loss for USB 3.1 Gen2 10 Gbps;
  • They are fully compliant to the latest USB 3.2 Appendix E requirements supporting 4-re-timer connectivity, with seamless daisy-chaining of four re-timers, meeting the USB 3.2 CTS requirements;
  • They are complete DisplayPort re-timers with Link Training Tunable PHY Repeater (LTTPR) mode and transparent mode with AUX snooper, guaranteeing a loss compensation to recover up to 20dB channel loss for DisplayPort HBR3 8.1 Gbps.

“We are very pleased with the market adoption of our USB-C re-timers as high-speed connections approach 10Gbps,” said Michael Ching, vice president of marketing for Analogix. “Having met the stringent requirements and extensive interoperability and compatibility testing of the PC industry, our re-timer solutions are market-proven, with consumer products available now, from the latest Intel Coffee Lake notebooks and desktop PCs, to Windows on ARM detachable convertible PCs, Nvidia G-Sync monitors, and USB-C accessories.”

The ANX74xx product family includes:

  • ANX7440 – integrated 10 Gbps re-timer and USB-C switch for DisplayPort over USB-C ports;
  • ANX7430 – integrated 10 Gbps re-timer and USB-C switch for USB 3.1 Gen2 USB-C ports;
  • ANX7490 – integrated 10 Gbps re-timer for USB 3.1 Gen2 USB Type-A, Type-B, and USB Type-C ports;
  • ANX7496 – integrated 8.1 Gbps DisplayPort re-timer for mini-DP, standard DisplayPort, and USB-C ports.

Demonstrations of Analogix’s high-speed signal conditioner solutions and their implementation in consumer devices are taking place during this week’s Computex 2018, Analogix exhibitor suite # 1140 & 1141 at The Grand Hyatt Taipei.

About Analogix Semiconductor

Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones, notebooks, and VR head mounted displays, to large, high-definition TVs and high-end graphics cards. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort under its SlimPort brand, including high-speed signal conditioners, and an industry leader in mobile display controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed by the Video Electronics Standards Association (VESA). SlimPort branded products are compliant with DisplayPort, Mobility DisplayPort (MyDP), and DisplayPort Alternate Mode over the USB Type-C connector.

For more information visit www.analogix.com and www.slimport.com, follow us on Twitter @Analogix and @SlimPortConnect, or connect with us on LinkedIn.

Analogix and SlimPort are trademarks or registered trademarks of Analogix Semiconductor, Inc. All other trademarks and trade names are the property of their respective owners.

Contact information

Analogix Media Contact
Gratia Stefan, 408-988-8848
marcom@analogix.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EESTTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EESTTiedote

ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EESTTiedote

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EESTTiedote

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EESTTiedote

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EESTTiedote

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme